EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

The prognostic value of the Merkel cell polyomavirus serum antibody test: A dual institutional observational study

David M Miller iD, Sophia Z Shalhout iD, Kayla M Wright, Matt A Miller, Howard L Kaufman, Kevin S Emerick, Harrison T Reeder, Ann W Silk iD, Manisha Thakuria

Cancer · 2024-08 · 130 (15) · 2670-2682

DOI: 10.1002/cncr.35314 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Cancer, online erschienen am 02.05.2024. Verfasst von David M Miller und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Carcinoma, Merkel Cell, Merkel cell polyomavirus, Skin Neoplasms, Antibodies, Viral. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: NCATS NIH HHS, Project Data Sphere, National Institutes of Health Award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Merkel cell carcinoma (MCC) is an aggressive cancer with often poor outcomes. Limited biomarkers exist for predicting clinical outcomes. The Merkel cell polyomavirus (MCPyV) serum antibody test (AMERK) has shown potential for indicating better recurrence‐free survival in a single‐institution study. The study aimed to evaluate the link between initial AMERK serostatus and survival. Secondary objectives included examining the relationship between initial AMERK titer levels and tumor burden.

Methods

A retrospective cohort study across two institutions analyzed patients tested with AMERK within 90 days of MCC diagnosis. Regression models assessed the association of survival outcomes with serostatus, considering various factors. The relationship between AMERK titer and tumor burden indicators was evaluated using ANOVA. Significance testing was exploratory, without a fixed significance level.

Results

Of 261 MCC patients tested, 49.4% were initially seropositive (titer ≥75). Multivariable analysis showed that seropositivity improved recurrence, event‐free, overall, and MCC‐specific survival rates. Strong associations were found between initial AMERK titer and clinical, tumor, and nodal stages, tumor size, and disease extent. Notably, improved survival with seropositivity was observed only in patients with localized disease at initial presentation.

Conclusion

Circulating antibodies to MCPyV oncoproteins, as indicated by the AMERK test, are linked with better survival in MCC patients with localized disease at presentation. This could enhance patient risk profiling and treatment personalization. The study's retrospective nature and exploratory analysis are key limitations. Plain Language Summary Merkel cell carcinoma (MCC) is a potentially aggressive skin cancer, and tools to predict patient outcomes are limited. A blood test called anti‐Merkel cell panel (AMERK), which checks for specific antibodies related to this cancer, might give us some clues. In this study, we looked at 261 MCC patients who took the AMERK test within 90 days of diagnosis. We found that patients with an initial positive AMERK result tended to have better outcomes, especially if their cancer was in the early stages. However, it is important to note that this study has limitations, including using retrospective data and exploratory analyses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Merkel CellMerkel cell polyomavirusSkin NeoplasmsAntibodies, ViralHumansFemaleMaleRetrospective StudiesAgedPrognosisMiddle AgedAged, 80 and overTumor Virus InfectionsPolyomavirus Infections

Stichwörter der Autor:innen

AMERKMerkel cell carcinomaMerkel cell polyomavirus serumantibodyblood‐based biomarker

Substanzen

Antibodies, Viral

Autor:innen und Institutionen

  • Department of Medicine, Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • Mike Toth Head and Neck Cancer Research Center, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA.
  • Department of Otolaryngology, Head and Neck Surgery, Division of Surgical Oncology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA.
  • Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA.

ORCID-Profile: David M Miller, Sophia Z Shalhout, Ann W Silk

Förderung

  • NCATS NIH HHS
  • Project Data Sphere
  • National Institutes of Health Award
  • ECOG-ACRIN Cancer Research Group

Zitieren

APA

Miller, D. M., Shalhout, S. Z., Wright, K. M., Miller, M. A., Kaufman, H. L., Emerick, K. S., Reeder, H. T., Silk, A. W., & Thakuria, M. (2024). The prognostic value of the Merkel cell polyomavirus serum antibody test: A dual institutional observational study. Cancer, 130(15), 2670-2682. https://doi.org/10.1002/cncr.35314

Vancouver

Miller DM, Shalhout SZ, Wright KM, Miller MA, Kaufman HL, Emerick KS, et al. The prognostic value of the Merkel cell polyomavirus serum antibody test: A dual institutional observational study. Cancer. 2024;130(15):2670-2682. doi:10.1002/cncr.35314

BibTeX
@article{Miller2024,
  author = {Miller, David M and Shalhout, Sophia Z and Wright, Kayla M and Miller, Matt A and Kaufman, Howard L and Emerick, Kevin S and Reeder, Harrison T and Silk, Ann W and Thakuria, Manisha},
  title = {The prognostic value of the Merkel cell polyomavirus serum antibody test: A dual institutional observational study},
  journal = {Cancer},
  year = {2024},
  volume = {130},
  number = {15},
  pages = {2670--2682},
  doi = {10.1002/cncr.35314}
}
Kostenlos starten →